TOSYALI secured 187 million Euro financing from Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) for its first phase of 1.2 GW solar investment
23.7.2026 15:13:20 CEST | news aktuell GmbH | Press Release
TOSYALI continues to accelerate its energy transition by securing long term international financing for supporting its decarbonization agenda and sustainability investments. The company has signed Export Finance Buyer Credit Agreements worth 187 million euros with BBVA, under Spanish Export Credit Agency Cesce’s cover, for Osmaniye and Niğde Projects in its first phase of solar power plant (SPP) investments with total capacity of 1.2 GW.

With an annual crude steel production capacity of 15 million tons, TOSYALI, one of the world’s leading global green steel producers, continues to strengthen its investments in sustainability and energy transformation funded through international financing sources.
TOSYALI recently signed 187 million Euros Export Finance Buyer Credit Agreement with BBVA under Cesce cover for Osmaniye and Niğde projects under the first phase of its 1.2 GW Solar Power Plant investment. The financing, mobilized in coordination with GE Vernova’s Financial Services business, will be utilized for the implementation of these two projects with total installed capacity of 261 MW.
This transaction represents GE Vernova’s first Spanish ECA-backed financing for a renewable energy project in Türkiye, further strengthening its track record of mobilizing approximately USD 850 million in solar financing in the market. It also expands the company’s local footprint, where its technology already supports approximately 3.5 GW of installed solar capacity.
Inogen (EPC Contractor) and GE Vernova Spain (technology provider) acted as key project stakeholders of Osmaniye and Niğde Projects.
This financing underpins international financial institutions’ confidence in TOSYALI’s long-term vision for green steel and energy transformation. At the same time, it demonstrates the company’s strong position in global financial markets and its ability to secure financing for sustainability-focused investments.
TOSYALI’s 1.2 GW solar power plant investments represent a follow-on investment on top of its existing 235 MW rooftop solar power plant capacity which was developed earlier as one of the world’s largest capacities in its segment. Today, with this new investment that will reach a total capacity of 1.4 GW, the company is progressively developing one of the world’s largest self-consumption-focused renewable energy projects.
Commenting on the financing agreement, Fuat TOSYALI, Chairman of TOSYALI Holding, said: “Energy transformation has become one of the most important factors determining competitiveness in industry today. As TOSYALI, we place sustainability at the center of our business and are transforming all of our processes, from production to energy, with a long-term perspective. Our solar power plant investments, which we are implementing with this vision and which will reach a total capacity of 1.4 GW, is not only investments aimed at meeting our own energy needs from renewable sources, but also a strategic transformation initiative that strengthens our energy independence and reinforces our global ambition in green steel production.
Strong international partnerships and access to sustainable financing sources are critical for the implementation of investments of this scale. Meanwhile, the 187 million Euros Export Finance Buyer Credit Agreement that we have signed with BBVA under Cesce cover is an important indication of the confidence that international financial institutions place in TOSYALI’s vision and sustainable growth strategy. Together with the strong collaboration we have established with GE Vernova and Inogen, we are bringing together advanced technology, engineering expertise and financing capabilities to deliver one of the world’s largest self-consumption-focused solar power plant projects. Through our renewable energy investments, we aim both to achieve our low-carbon production targets and to further strengthen our leading position in the global green steel industry.”
Prof. Ali Murat SOYDAN, Chairman of Inogen Group: “Green transformation in industry is one of the main agendas of our country, as it is all over the world. Here, together with our solution partners, we have adopted a one-stop shop model in the energy sector in Türkiye for many years, and today we are very pleased to be able to organize the experience we have gained here in a way that can meet the needs of our industrialists who are committed to green transformation. Looking at the issue only from a financial point of view does not create a very healthy perspective; creating the most suitable solution for the need with optimal costs through the most accurate planning requires great experience. As Inogen Group, with more than 15 years of experience combined with 2000 employees in 7 different countries, and our strategic collaboration with GE Vernova, we have gained the ability to perform this optimization. I would also like to thank Mr. Fuat TOSYALI, who has supported this project from day one and carried out the investment process with determination.”
Contacts
Serap ÖztürkDirector of Media Relations
sozturk@medyaevi.com.trImages

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Sustainable Business: The Companies of Schwarz Group Present Roadmap to Combat Climate Risks and Resource Scarcity22.7.2026 09:40:33 CEST | Press Release
Seventh Sustainability Report highlights expansion of energy and resource sovereignty External ESG rating confirms effective alignment of sustainability with strategic risk management Climate transition plan serves as central instrument for future-proofing business processes
Polpharma Strengthens Its Position in Central and Eastern Europe – Biofarm, the Leader of the Romanian Market, Joins the Group21.7.2026 11:00:00 CEST | Press Release
Warsaw, 21.07.2026 - Polpharma Group has completed the acquisition of the Romanian pharmaceutical company Biofarm. The transaction is a clear step in the execution of the Group’s growth strategy and strengthens its position in Central and Eastern Europe. With Biofarm joining the Group, Polpharma is expanding the scale of its operations, reinforcing its presence in key regional markets, and creating new opportunities to improve patients’ access to trusted medicines across the region and beyond.
The Quality Group grows H1 revenue by more than 40% to over €850 million21.7.2026 10:04:58 CEST | Press Release
H1 2026 revenue reached €850 million – up more than 40% versus H1 2025 Demand continues to grow as more consumers seek better nutrition, health and performance solutions Company growth is broad-based, reflecting successful execution of strategies across brands, product categories, channels, and markets
Battery electric vehicle prices fell 18% and model choice quadrupled between 2020 and 202520.7.2026 06:00:00 CEST | Press Release
New study analyzes EV purchase prices and market trends in Germany, Europe's largest car market
Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich16.7.2026 10:32:18 CEST | Press Release
Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients. Joining the CNATM provides Grünenthal with a valuable platform to strengthen its oligonucleotide drug discovery capabilities and connect its growing internal expertise with one of Germany’s leading academic and biotech innovation ecosystems. Over the last few years, Grünenthal has built strategic in-house capabilities to advance oligonucleotide modalities, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA), as potential therapeutic approaches for pain and related neurological indications. One of Grünenthal’s key objectives for the collaboration
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom